Black race is an independent prognostic factor for lower survival outcomes in AML, regardless of cytogenetics. Black patients with NPM1 mutations had poorer overall survival compared to White patients ...
AML is a hematologic cancer that is clinically heterogeneous, with a wide range of clinical outcomes. DNA methylation changes are a hallmark of AML but are not routinely used as a criterion for risk ...
The study may help explain why some patients are more prone to relapse following a complete response to induction therapy, as indicated by measurable residual disease (MRD) status and 2017 European ...
Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk ...
SAN DIEGO, March 13, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study published in the American Journal of Hematology demonstrating the potential utility of ...
This study is led by Dr. Hua You (Children’s Hospital of Chongqing Medical University, Chongqing, China). As our understanding of AML biology, cytogenetic and molecular profiles, and the emergence of ...
Asian patients with newly diagnosed acute myeloid leukemia (AML) may have superior overall survival (OS) outcomes compared with White patients, though further data are needed to corroborate this ...
Bionano announced a significant study published in the American Journal of Hematology demonstrating the utility of optical genome mapping (OGM) in detecting structural variants associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback